Ligand Pharmaceuticals/$LGND
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Ticker
$LGND
Sector
Primary listing
Employees
68
Headquarters
Website
LGND Metrics
BasicAdvanced
$3.2B
-
-$4.00
0.74
-
Price and volume
Market cap
$3.2B
Beta
0.74
52-week high
$169.49
52-week low
$93.58
Average daily volume
267K
Financial strength
Current ratio
5.452
Quick ratio
4.594
Long term debt to equity
0.559
Total debt to equity
0.693
Interest coverage (TTM)
-4.71%
Profitability
EBITDA (TTM)
19.728
Gross margin (TTM)
57.46%
Net profit margin (TTM)
-40.44%
Operating margin (TTM)
-7.62%
Effective tax rate (TTM)
10.22%
Revenue per employee (TTM)
$2,760,000
Management effectiveness
Return on assets (TTM)
-0.98%
Return on equity (TTM)
-9.46%
Valuation
Price to revenue (TTM)
16.77
Price to book
3.87
Price to tangible book (TTM)
6.72
Price to free cash flow (TTM)
58.67
Free cash flow yield (TTM)
1.70%
Free cash flow per share (TTM)
2.825
Growth
Revenue change (TTM)
40.54%
Earnings per share change (TTM)
-270.58%
3-year revenue growth (CAGR)
-0.14%
10-year revenue growth (CAGR)
10.20%
3-year earnings per share growth (CAGR)
103.33%
10-year earnings per share growth (CAGR)
9.93%
What the Analysts think about LGND
Analyst ratings (Buy, Hold, Sell) for Ligand Pharmaceuticals stock.
Bulls say / Bears say
Royalty revenue in Q2 2025 increased 57% year-over-year to $36.4 million, pushing total revenue up 15% and leading management to raise 2025 guidance to $200 million–$225 million and adjusted EPS to $6.70–7.00.
Merck’s $10 billion acquisition of Verona Pharma validates Ligand’s royalty portfolio, since Ligand receives a 3% royalty on Ohtuvayre, supporting strong future cash flow.
Oppenheimer increased its price target on LGND to $167 and kept an Outperform rating after the solid Q2 report, reflecting strong analyst confidence in Ligand’s growth outlook.
Contract revenue in the first half of 2025 dropped to $7.3 million from $13.5 million a year earlier, highlighting the unpredictability of milestone-based income from partner programs.
Research and development expenses jumped to $56.7 million in H1 2025 from $11.3 million in H1 2024, mainly due to a $44.3 million one-time expense tied to the Castle Creek royalty financing, raising concerns about high cash burn and margin compression.
Ligand booked a $26.2 million impairment on its soticlestat royalty asset after Phase 3 trial failures, showing the risk of sudden write-downs if partner programs do not succeed.
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
LGND Financial Performance
Revenues and expenses
LGND Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ligand Pharmaceuticals stock?
Ligand Pharmaceuticals (LGND) has a market cap of $3.2B as of September 16, 2025.
What is the P/E ratio for Ligand Pharmaceuticals stock?
The price to earnings (P/E) ratio for Ligand Pharmaceuticals (LGND) stock is 0 as of September 16, 2025.
Does Ligand Pharmaceuticals stock pay dividends?
No, Ligand Pharmaceuticals (LGND) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Ligand Pharmaceuticals dividend payment date?
Ligand Pharmaceuticals (LGND) stock does not pay dividends to its shareholders.
What is the beta indicator for Ligand Pharmaceuticals?
Ligand Pharmaceuticals (LGND) has a beta rating of 0.74. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.